BioNTech SE has formalised plans to raise approximately $250 million by way of an initial public share offering on the US Nasdaq market to support its portfolio of personalised medicines for cancer and infectious diseases. The company plans to offer 13.2 million American Depositary Shares (ADSs) to the public while underwriters will have a 30-day option to buy up to an additional 1.98 million ADSs.
JP Morgan, Bank of America Merrill Lynch, UBS Investment Bank and SVB Leerink are acting as lead joint book running managers.